Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical Inc
Newave Pharmaceutical Inc
MacroGenics
City of Hope Medical Center
City of Hope Medical Center
Stanford University
University of California, Davis
Xencor, Inc.
Astellas Pharma Inc
Stanford University
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
University of Wisconsin, Madison
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Massachusetts General Hospital
University of Louisville
Alliance for Clinical Trials in Oncology
Morphotek
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Indiana University
Indiana University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northwestern University
Northwestern University
Mayo Clinic
NYU Langone Health
Roswell Park Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Arizona
Virginia Commonwealth University